Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Open and Multicenter Phase I/II Clinical Study to Evaluate the Safety and Efficacy of U16 Injection in the Treatment of Refractory/Recurrent B-cell Non-Hodgkin's Lymphoma (r/r B-NHL)

NCT05768529 is registered in ClinicalTrials.gov with Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd as lead sponsor.

NCT NCT05768529
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05768529 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Open and Multicenter Phase I/II Clinical Study to Evaluate the Safety and Efficacy of U16 Injection in the Treatment of Refractory/Recurrent B-cell Non-Hodgkin's Lymphoma (r/r B-NHL)
Lead sponsor
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 28, 2023
Completion date
December 31, 2030
Enrollment
100 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory non-hodgkin's lymphoma